{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:18:44Z","timestamp":1783955924043,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ygyno.2014.10.010","type":"journal-article","created":{"date-parts":[[2014,10,25]],"date-time":"2014-10-25T01:26:56Z","timestamp":1414200416000},"page":"121-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival"],"prefix":"10.1016","volume":"136","author":[{"given":"J.","family":"Tate Thigpen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2014.10.010_bb0005","series-title":"Cancer Facts & Figures, 2013","author":"American Cancer Society","year":"2013"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0010","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/AOG.0b013e318264f794","article-title":"Ten-year relative survival for epithelial ovarian cancer","volume":"120","author":"Baldwin","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0020","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM199503093321002","article-title":"The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer","volume":"332","author":"van der Burg","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0035","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J","article-title":"A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study","volume":"57","author":"Omura","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0040","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0045","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.5008","article-title":"Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT)","volume":"29","author":"Buckanovich","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00000421-199502000-00004","article-title":"A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study","volume":"18","author":"Look","year":"1995","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0070","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0075","doi-asserted-by":"crossref","first-page":"393s","DOI":"10.1200\/jco.2010.28.15_suppl.5013","article-title":"Phase II study of NKTR-102 in women with platinum resistant\/refractory ovarian cancer","volume":"28","author":"Vergote","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2014.10.010_bb0080","article-title":"AGO-OVAR 12: a randomized placebo-controlled GCIG\/ENGOT-intergroup phase III trial of standard frontline chemotherapy +\/\u2212 nintedanib for advanced ovarian cancer","volume":"23","author":"du Bois","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0090","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0095","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.lba5006","article-title":"Results of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer","volume":"29","author":"Kristensen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0100","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0105","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0115","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.1997.15.12.3507","article-title":"Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"15","author":"Thiesse","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/PL00011706","article-title":"Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer","volume":"3","author":"Yoshida","year":"2000","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0360-3016(01)01615-7","article-title":"Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study","volume":"51","author":"Werner-Wasik","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF02967580","article-title":"Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer","volume":"9","author":"Kimura","year":"2002","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1259\/bjr.75.899.750903","article-title":"Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria","volume":"75","author":"Trillet-Lenoir","year":"2002","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0145","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1259\/bjr.73.875.11144795","article-title":"CT assessment of tumour response to treatment: comparison of linear, cross-sectional and volumetric measures of tumour size","volume":"73","author":"Sohaib","year":"2000","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0150","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1259\/bjr.74.887.740983","article-title":"The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists","volume":"74","author":"Padhani","year":"2001","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0160","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1200\/JCO.2006.06.5599","article-title":"Measures of response: RECIST, WHO, and new alternatives","volume":"24","author":"Jaffe","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jnci\/92.3.179","article-title":"Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?","volume":"92","author":"Gehan","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0170","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0175","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","article-title":"IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer","volume":"17","author":"Anglesio","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0180","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2013shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0185","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2174\/15680096113139990002","article-title":"Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways","volume":"13","author":"Galic","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0190","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0195","series-title":"ABRAXANE\u00ae for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)","year":"2013"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0200","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0210","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1200\/JCO.2004.10.028","article-title":"Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?","volume":"22","author":"Gronlund","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0215","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.12-1-72","article-title":"Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients","volume":"12","author":"Coleman","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0220","unstructured":"Food and Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. file:\/\/\\\\dvcpa_refman\\refmandb\\New PDFs-2-07\\ucm071590.pdf. Accessed July 30, 2013"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0225","series-title":"TAXOL\u00ae (paclitaxel) Injection","year":"2011"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0230","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/PPO.0b013e3181b9c602","article-title":"Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials","volume":"15","author":"Buyse","year":"2009","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0235","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ygyno.2007.08.092","article-title":"Clinical trial endpoints in ovarian cancer: report of an FDA\/ASCO\/AACR Public Workshop","volume":"107","author":"Bast","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0240","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results","volume":"92","author":"Piccart","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0255","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"issue":"Suppl. 8","key":"10.1016\/j.ygyno.2014.10.010_bb0260","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdi962","article-title":"Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens","volume":"16","author":"Thigpen","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0265","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0270","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1078-0432.CCR-13-0869","article-title":"PFS: the endpoint we love and love to hate","volume":"19","author":"Bates","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0275","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5081","article-title":"Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC)","volume":"30","author":"Sjoquist","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0280","author":"Brady"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0285","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","volume":"24","author":"du Bois","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0290","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"International Collaborative Ovarian Neoplasm Group","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0295","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0300","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1995.13.7.1589","article-title":"Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study","volume":"13","author":"McGuire","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0305","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"7","author":"Omura","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0310","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMoa041125","article-title":"Secondary surgical cytoreduction for advanced ovarian carcinoma","volume":"351","author":"Rose","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0315","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(98)04119-1","article-title":"ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0320","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/1078-0432.CCR-12-2934","article-title":"Overview: progression-free survival as an endpoint in clinical trials with solid tumors","volume":"19","author":"Korn","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0325","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-12-2938","article-title":"Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials","volume":"19","author":"Sridhara","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0330","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/bjc.1989.234","article-title":"The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer","volume":"60","author":"Bronchud","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0340","series-title":"Presentation at: the FDA\/ASCO Public Workshop on Clinical Trial End Points in Ovarian Cancer; April 26, 2006; Bethesda, MD","article-title":"Regulatory background","author":"Pai-Scherf","year":"2006"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0345","series-title":"GEMZAR (gemcitabine for injection) Powder, Lyophilized, For Solution For Intravenous Use","year":"2011"},{"key":"10.1016\/j.ygyno.2014.10.010_bb0350","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.lba5002","article-title":"AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)","volume":"30","author":"Pujade-Lauraine","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814013705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:00:17Z","timestamp":1598414417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814013705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0090825814013705"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.10.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}